Compare Amgen, Inc. (AMGN) vs Progressive Corp (PGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Progressive Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Progressive Corp trades at $231.86 (market cap $134.33B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Progressive Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals.
| AMGN | PGR | |
|---|---|---|
Market Cap | $196.12B | $134.33B |
Sector | Health | Financials |
52-Week High | $388.16 | $252.68 |
52-Week Low | $271.18 | $190.40 |
Enterprise Value | $241.41B | $142.55B |
Dividend Yield | 2.77% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Progressive (PGR) trades at $230.72, up 0.52% on the day, with a bullish technical outlook indicated by moving averages and strong support at $228. The stock shows robust fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income surging to $11.3B. Recent earnings beats and a 36% jump in May 2026 net income highlight operational strength. The company maintains a solid net income margin of 12.93% and an impressive ROE of 37.9%.
The outlook for PGR is positive, supported by consistent earnings outperformance and analyst consensus pointing to upside with a $239.75 price target. Key risks include competitive pressures in the insurance sector and potential macroeconomic headwinds affecting consumer spending. Institutional sentiment is mixed but leans bullish, with 39% of analysts rating it a buy. The stock presents a compelling opportunity for growth investors seeking exposure to a financially healthy insurer.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
